Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
P/E ratio for Collegium Pharmaceutical, Inc. (COLL)
P/E ratio as of 2023: 21.57
According to Collegium Pharmaceutical, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.57. At the end of 2022 the company had a P/E ratio of -31.39.
P/E ratio history for Collegium Pharmaceutical, Inc. from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 21.57 |
| 2022 | -31.39 |
| 2021 | 9.13 |
| 2020 | 25.76 |
| 2019 | -84.50 |
| 2018 | -14.43 |
| 2017 | -7.46 |
| 2016 | -4.01 |
| 2015 | -13.66 |
| 2014 | -5.12 |
| 2013 | -5.67 |